Calamos Advisors’s AbbVie ABBV Stock Holding History

Calamos Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-263,000	Closed	-$19.1M	–	744
2019 Q2	$19.1M	Buy	+263,000	New	+$20.7M	0.11%	233
2018 Q1	–	Sell	-50,200	Closed	-$4.86M	–	600
2017 Q4	$4.86M	Buy	+50,200	New	+$4.73M	0.02%	396

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Calamos Advisors's ABBV Position: Q2 2026 in Review

Calamos Advisors reduced its AbbVie (ABBV) stake by 17% in Q2 2026, selling an estimated $18M and leaving 399,893 shares worth $101M. The position accounts for 0.33% of the portfolio, ranked #61.

Calamos Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $107M in Q1 2018. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Calamos Advisors held 399,893 shares of AbbVie worth $101M as of Q2 2026.
Calamos Advisors sold 83,777 AbbVie shares in Q2 2026, an estimated $18M.
AbbVie made up 0.33% of Calamos Advisors's portfolio in Q2 2026, its #61 holding.
Calamos Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
Calamos Advisors's AbbVie position peaked at $107M in Q1 2018.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.